Jun 01, 2020
Henlius and Accord Receive Positive CHMP Opinion for Oncology Biosimilar, HLX02 (Trastuzumab)
Apr 23, 2020
Henlius receives EU GMP Certificate for HLX02 (Trastuzumab for Injection)
Apr 23, 2020
New Early Breast Cancer Drug Available Now In Singapore
Mar 24, 2020
Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update
Feb 19, 2020
Big Advances in Breast Cancer Screening Creating Sizable Opportunities
Jan 07, 2020
Hummingbird Bioscience Publishes Preclinical Data Demonstrating Efficacy of HMBD-001 in HER3 Driven Cancers
Dec 20, 2019
FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
Dec 02, 2019
New Early Breast Cancer Drug Approved by Singapore Health Sciences Authority
Dec 02, 2019
Mylan and Biocon Launch Trastuzumab Biosimilar, Ogivri(TM) (trastuzumab-dkst), in the U.S.
Nov 28, 2019
Health Canada approves Kadcyla® (trastuzumab emtansine) for the treatment of HER2-positive early breast cancer after surgery(1)
Sep 23, 2019
ESMO Annual Meeting 2019: Menarini Ricerche Presents the Preclinical Characterization of MEN1611, a Novel PI3K Inhibitor in Development for the Treatment of Breast Cancer
Sep 16, 2019
Anixa Biosciences Congratulates Scientific Advisory Board Member Dr. H. Michael Shepard as a 2019 Lasker Award Honoree
Sep 10, 2019
Lasker Foundation Announces 2019 Lasker Awards For Basic And Clinical Medical Research And Public Service
Sep 09, 2019
Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast Cancer
Sep 03, 2019
North America accounted for the largest share, accounting for approximately 30% of the global market, in 2017
Jul 18, 2019
Amgen And Allergan's MVASI(TM) (bevacizumab-awwb) And KANJINTI(TM) (trastuzumab-anns) Now Available In The United States
Jun 21, 2019
European Medicines Agency Accepted First "China-Developed" Biosimilar - Henlius HLX02 Marketing Authorization Application for Review
Jun 13, 2019
FDA Approves Amgen And Allergan's KANJINTI(TM) (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
May 15, 2019
Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and Promises of Oncology Portfolio
May 15, 2019
NeuClone to Initiate Phase I Clinical Trial of Stelara (Ustekinumab) Biosimilar, the Second Biosimilar from the 10-product Portfolio with Serum Institute